Hepatocellular Carcinoma Immunopathogenesis: Clinical Evidence for Global T Cell Defects and an Immunomodulatory Role for Soluble CD25 (sCD25)
- 28 August 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Digestive Diseases and Sciences
- Vol. 55 (2), 484-495
- https://doi.org/10.1007/s10620-009-0955-5
Abstract
Background The mechanisms involved in hepatocellular carcinoma (HCC) establishing an immunologically tolerogenic tumor environment remain poorly characterized. Aims This study evaluates effector T cell responses and soluble IL-2 receptor alpha chains (sCD25) in relation to HCC stage/survival and characterizes the impact of sCD25 on effectors. Methods Effector cell responses with serum from HCC patients and in serum free conditions were assessed by IFN-γ ELISpot, proliferation and ATP production assays at baseline, after depletion of sCD25, and after supplementation with recombinant sCD25. Sera sCD25 were measured by ELISA and any relationship with stage/survival was determined. Results Hepatocellular carcinoma patients had marked global impairment in T cell responses at baseline which correlate with tumor burden and poor outcome. The impairment in immune responses is characterized by low IFN-γ production, cell proliferation, and ATP production. Effector responses are impaired by serum from HCC patients in a dose-dependent manner, implicating soluble factors in the observed immunosuppression. Significant elevations in serum levels of sCD25 are found in patients with HCC, which correlate with tumor burden and a worse survival. T cell reactivity is inversely proportional to serum level of sCD25. Impaired T cell responses improve with sCD25 depletion from HCC serum or IL-2 supplementation suggesting impairment in IL-2 signaling. In contrast, adding increasing doses of sCD25 suppresses effector T cells, which partly involves induction of apoptosis. Conclusions These findings show that HCC patients have blunted T cell immunity that is partly related to elevated levels of sCD25, supporting a novel immuno-inhibitory role for this soluble receptor.Keywords
This publication has 26 references indexed in Scilit:
- Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patientsLiver Transplantation, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T CellsGastroenterology, 2008
- Serum soluble interleukin 2 receptor α in human cancer of adults and children: a reviewBiomarkers, 2008
- Hepatocellular carcinoma cell supernatants increase expansion and function of CD4+CD25+ regulatory T cellsLaboratory Investigation, 2007
- Management of hepatocellular carcinomaHepatology, 2005
- TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-SignalingImmunity, 2004
- Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effectHepatology, 2003
- Circulating IL‐6 and sIL‐6R in Patients with Hepatocellular CarcinomaAnnals of the New York Academy of Sciences, 2002
- Soluble Interleukin 2 Receptors Released from Mitogen Stimulated Human Peripheral Blood Lymphocytes Bind Interleukin 2 and Inhibit IL2 Dependent Cell ProliferationImmunological Investigations, 1989